Tier 2 — strong

Effect of Berberine Hydrochloride on the Diversity of Intestinal Flora in Parkinson's Disease Patients

Li J, Meng P, Zhang J, He M
Contrast media & molecular imaging 2022 2022:8381870

Bibliography

PubMed
PMID 35685661
PubMed Central
PMC9170458
DOI
10.1155/2022/8381870
Funding
Funding was not established from the accessible source; this is not a declaration of no funding.
Competing interests
The authors declared no competing interests in the publication.

Study snapshot

DesignRandomized controlled human trial
ModelHuman participants; see population
Sample68 Parkinson disease patients; 34 per arm
InterventionBerberine hydrochloride plus usual treatment versus usual treatment
Duration3 months
EndpointsStool microbial diversity/composition; IL-6, IL-8 and TNF-alpha

What the study showed, in plain terms

Gut microbial and inflammatory measures differed after adjunctive berberine.

Key findings

  • Gut microbial and inflammatory measures differed after adjunctive berberine.

What this study can and cannot tell us

The reported endpoints do not demonstrate slowed Parkinson disease progression or meaningful motor benefit.

Related papers in the corpus

Tier 2
Berberine improves negative symptoms and cognitive function in patients with chronic schizophrenia via anti-inflammatory effect: a randomized clinical trial
Pu Z et al. · Chinese medicine · 2023
Tier 2
Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial
Chan M et al. · Psychiatry and clinical neurosciences · 2022
Tier 4
Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin
Qiu Y et al. · Asian journal of psychiatry · 2022
Tier 2
Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia
Li M et al. · European archives of psychiatry and clinical neuroscience · 2022
Tier 2
The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial
Li M et al. · Psychiatry research · 2021

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology